News on Efavirenz from BioPortfolio.com http://www.BioPortfolio.com Consolidated Efavirenz news from BioPortfolio.com Wed, 10 Feb 2010 10:17:12 GMT en Even very low levels of pre-existing resistance increase risk of efavirenz failurehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039311&HITNO=0&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039311&THISHREF=http://c.moreover.com/click/here.pl%3fz2538010137%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039311&HITNO=0&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039311&THISHREF=http://c.moreover.com/click/here.pl%3fz2538010137%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAidsmap: Hard-to-detect HIV mutants boost antiretroviral failurehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039506&HITNO=1&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039506&THISHREF=http://c.moreover.com/click/here.pl%3fz2538167843%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039506&HITNO=1&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039506&THISHREF=http://c.moreover.com/click/here.pl%3fz2538167843%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comReuters Health: Less resistance with FTC than 3TC when combined with tenofovirhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030678&HITNO=2&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030678&THISHREF=http://c.moreover.com/click/here.pl%3fz2533758995%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030678&HITNO=2&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030678&THISHREF=http://c.moreover.com/click/here.pl%3fz2533758995%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAidsmap: MEXICO: Prospective, Randomized, Open-Label Trial of Efavirenz vs. Lopinavir/Ritonavir in HIV+ Treatment-Naivehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018146&HITNO=3&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018146&THISHREF=http://c.moreover.com/click/here.pl%3fz2525498847%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018146&HITNO=3&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018146&THISHREF=http://c.moreover.com/click/here.pl%3fz2525498847%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAEGIS: Efavirenz-Based HAART Most Effective First Treatment of Advanced HIV Infectionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000056&HITNO=4&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000056&THISHREF=http://c.moreover.com/click/here.pl%3fz2517811084%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000056&HITNO=4&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000056&THISHREF=http://c.moreover.com/click/here.pl%3fz2517811084%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAbstracts in Hematology and Oncology: Efavirenz-Based HAART Most Effective First Treatment of Advanced HIV Infectionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999396&HITNO=5&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999396&THISHREF=http://c.moreover.com/click/here.pl%3fz2517426810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999396&HITNO=5&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999396&THISHREF=http://c.moreover.com/click/here.pl%3fz2517426810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedscape: Efavirenz-Loaded Polymeric Micelles for Pediatric Anti-HIV Pharmacotherapy With Significantly Higher Oral Bioahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988197&HITNO=6&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988197&THISHREF=http://c.moreover.com/click/here.pl%3fz2510684281%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988197&HITNO=6&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988197&THISHREF=http://c.moreover.com/click/here.pl%3fz2510684281%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedscape: Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per sharehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987356&HITNO=7&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987356&THISHREF=http://c.moreover.com/click/here.pl%3fz2509802521%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987356&HITNO=7&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987356&THISHREF=http://c.moreover.com/click/here.pl%3fz2509802521%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Letter: Caution urged when switching regimens (AEGiS.org)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987231&HITNO=8&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987231&THISHREF=http://c.moreover.com/click/here.pl%3fz2509710209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987231&HITNO=8&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987231&THISHREF=http://c.moreover.com/click/here.pl%3fz2509710209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAEGIS: Vicriviroc, a CCR5 Inhibitor, Hits Major Roadblock in Developmenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986504&HITNO=9&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986504&THISHREF=http://c.moreover.com/click/here.pl%3fz2509213279%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986504&HITNO=9&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986504&THISHREF=http://c.moreover.com/click/here.pl%3fz2509213279%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comThe Body: Gilead Sciences Announces Notification of ANDA Filing for Vireadhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986256&HITNO=10&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986256&THISHREF=http://c.moreover.com/click/here.pl%3fz2509028270%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3986256&HITNO=10&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3986256&THISHREF=http://c.moreover.com/click/here.pl%3fz2509028270%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: B-MS looking at acquisitions and definitely 'not for sale'http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3982536&HITNO=11&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3982536&THISHREF=http://c.moreover.com/click/here.pl%3fz2507489371%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3982536&HITNO=11&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3982536&THISHREF=http://c.moreover.com/click/here.pl%3fz2507489371%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Times: Gilead Sciences Announces Notification of ANDA Filing for Viread ,http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981433&HITNO=12&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981433&THISHREF=http://c.moreover.com/click/here.pl%3fz2506986029%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981433&HITNO=12&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981433&THISHREF=http://c.moreover.com/click/here.pl%3fz2506986029%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Gilead Sciences Announces Notification Of ANDA Filing For Viread(R)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980224&HITNO=13&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980224&THISHREF=http://c.moreover.com/click/here.pl%3fz2506270300%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980224&HITNO=13&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980224&THISHREF=http://c.moreover.com/click/here.pl%3fz2506270300%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMediLexicon: In 2018, Coformulation of Rilpivirine and Truvada Will Achieve Blockbuster Sales of More Than $2 Billion in thhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3974329&HITNO=14&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3974329&THISHREF=http://c.moreover.com/click/here.pl%3fz2503425713%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3974329&HITNO=14&MSIZE=111&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Efavirenz&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3974329&THISHREF=http://c.moreover.com/click/here.pl%3fz2503425713%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRehab Manegement: